Table 1.

Study population characteristics; n [%].

Gender
Male	9 [31%]
Female	20 [69%]
Median age at surgery, years [range]	38 [16–64]
Disease duration in years [range]	8 [0–34]
Montréal classification
Age [years]
A1 [< 17]	5 [17%]
A2 [17–40]	18 [62%]
A3 [> 40]	6 [21%]
Location
L1 [terminal ileum]	22 [76%]
L3 [ileocolic]	7 [24%]
Behaviour
B1 [non structuring, non penetrating]	-
B2 [stricturing]	26 [90%]
B3 [penetrating]	3 [10%]
P [anal involvement]	4 [14%]
Preoperative Crohn’s medication
None	6 [21%]
Anti-TNF alpha	16 [76%]
Mesalazine	3 [10%]
Vedoluzimab	1 [3%]
Methylprednisolone	2 [7%]
Budesonide	4 [14%]
Smoking	11 [38%]

TNF, tumour necrosis factor.